Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Clinical Trial

Skye Bioscience Selects NextPharma As Phase 2 Contract Drug Manufacturer

Skye Bioscience, Inc. (OTCQB: SKYE) , a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has selected NextPharma as its contract manufacturing organization (“CMO”) for its Phase 2 clinical trial mat

Benzinga

Phase 3 Trial On Ketamine Therapy Gets Almost $2M From UK State Funding

Biotech psychedelics company Awakn Life Sciences Corp. (OTCQB: AWKNF) has been granted funding for 66% of the costs from its phase 3 clinical trial on

Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Recap of Tuesday's Biotech Catalysts - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.

Benzinga

Scots nurse with terminal cancer needs £50,000 for treatment that could add years to life

Sarah McCrimmon, from Potterhill in Paisley, has been given hope of recovery from a rare form of kidney cancer that has blighted her life since she was 13.

Daily Record

Alterity Commences Mid-Stage Neurodegenerative Disorder Study

Alterity Therapeutics (NASDAQ: ATHE) doses first subject in its Phase 2 clinical trial of lead candidate ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.

Benzinga

Ayala Reveals Positive Results From Phase 2/3 Desmoid Tumors Study

Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) announced positive interim results from Part A of the ongoing RINGSIDE Pivotal Phase 2/3 clinical trial evaluating AL102 in desmoid tumors.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Dyne's Shares Gain After FDA Removed Clinical Hold On Muscular Disease Study

Dyne Therapeutics (NASDAQ: DYN) announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and cleared its Investigational New Drug (IND) application to initiate a clinical trial of its drug DYNE-25.

Benzinga

Clinical trial into potential cancer vaccine 'shows early promising results'

The vaccine, which has been codenamed TG4050, uses similar technology to that of the coronavirus jabs.

Daily Record

Edinburgh mum's persistent cough turned out to be advanced breast cancer

Lesley Stephen was diagnosed with incurable secondary breast cancer in 2014 and just as she thought her time was coming to an end, she found a 'miracle' in a patient trial.

Edinburgh Live

Indian-origin woman gets cancer-free following drug trial in UK

Miracles happen when science progresses! Jasmin David, a 51-year-old Indian-origin woman from Manchester, was given just months to live a few years ago due to breast cancer. Now, doctors have declared that she is showing no evidence of cancer, after undergoing a clinical trial at a UK hospital.

The Times of India

Woman given one year to live is now cancer-free after experimental treatment

Jasmin David took part in a clinical trial with experimental medicines

The Independent UK

Meet the NI woman aiming to improve lives of cancer patients with innovative technology

The technology is preparing for its first human clinical trial

Belfast Live

Global Primordium prostate cancer trial begins with Bundaberg man the first participant

When John Adams' cancer resurfaced last year, he thought he would have to travel hundreds of kilometres for treatment. But with promising early results, an Australian-first clinical trial is allowing him to receive care from the comfort of his home.

ABC News

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

NeuroSense Shares Surge On Encouraging Data From Alzheimer's-Associated Biomarker Study

NeuroSense Therapeutics Ltd (NASDAQ:NRSN) has announced results from a biomarker study to evaluate the potential of CogniC, a combination drug for Alzheimer's disease (AD). Earlier this week, NeuroSense reported results from a stage III ALS Biomarker study evaluating PrimeC. Preliminary results showed that levels of disease-related biomarkers in people with ALS were unchanged, in contrast…

Benzinga

Corcept Therapeutics Commences Late-Stage Ovarian Cancer Study

Corcept Therapeutics (NASDAQ: CORT) has initiated pivotal Phase 3 clinical trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.

Benzinga

FDA Green Lights Ceruvia's Phase 2 Psilocybin Trial Program For Obsessive-Compulsive Disorder Treatment

Clinical-stage biopharma company Ceruvia Lifesciences recently received FDA approval for its Investigational New Drug (IND) application for a Phase 2 clinical trial to determine the efficacy and safety of proprietary synthetic psilocybin (SYNP-101) in treating obsessive-compulsive disorder (OCD).&nbs

Benzinga

Revive Therapeutics Data Access Plan Approved By The FDA; Partial Unblinded Data In Company Hands

Revive Therapeutics Ltd. (OTC: RVVTF) moved closer towards potential endpoint change in their Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine to treat COVID-19.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Oyster Point Outlines Restructuring Plan With Savings Of Up To $48M In 2023

Oyster Point Pharma Inc (NASDAQ:OYST) will implement an operating expense streamlining plan to reduce employee and non-employee expenses (up to 50 roles) across the organization. The company plans to continue to drive the launch of Tyrvaya with approximately 150-200 field-based sales resources. The plan is expected to reduce operating expenses by approximately $6…

Benzinga

Jazz Pharmaceuticals' Late-Stage Multiple Sclerosis Study Misses Primary Endpoint

Jazz Pharmaceuticals (NASDAQ: JAZZ) announced top-line results from the Phase 3 clinical trial investigating nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in individuals with multiple sclerosis (MS).

Benzinga

Soligenix Gets FDA Nod For Mid-Stage Psoriasis Study

The U.S. Food and Drug Administration (FDA) has cleared Soligenix’s (NASDAQ: SNGX) Investigational New Drug (IND) application for Phase 2a clinical trial Evaluating SGX302 in the treatment of patients with Mild-to-Moderate Psoriasis.

Benzinga

Why Kezar Life Sciences Stock Is Soaring Today

Kezar Life Sciences Inc (NASDAQ: KZR) shares are surging Tuesday after the company announced topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib.

Benzinga

Cybin's Psilocybin Analog CYB003 Gets FDA Clearance For Trial To Potentially Treat Major Depressive Disorder

Psychedelic biopharma company Cybin Inc. (NEO: CYBN) has received FDA Investigational New Drug Application (IND) approval for a Phase 1/2a clinical trial evaluating its proprietary CYB003 for treating major depressive disorder (MDD).

Benzinga

Why Is Kezar Life Sciences Surging By 78%? 25 Stocks Moving In Tuesday's Pre-Market Session

Gainers Kezar Life Sciences, Inc. (NASDAQ: KZR) rose 78% to $10.29 in pre-market trading after the company reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active lupus nephritis (LN).

Benzinga

Kezar Life Shares Shoot Higher After Positive Results From Mid-Stage Study Of Kidney Disease Candidate

Kezar Life Sciences, Inc. (NASDAQ: KZR) reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active lupus nephritis (LN).

1 … 15 16 17 18

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

US Food and Drug Administration

63 stories

Paisley Daily Express

37 stories

Rhythm Pharmaceuticals

30 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.